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ABSTRACT  
Diabetes mellitus is rising globally touching more than 180 million people worldwide. This is prevailing mostly in type 2 diabetes and according 
to WHO report the incidence is likely to be more than doubled by 2030. α-Glucosidase inhibitors work by reducing the amount of glucose that 
the intestines absorb from food. In this work, forty-five benzimidazole analogues were studied using 3D QSAR, HQSAR, pharmacophore 
mapping and based on their results 60 compounds were designed. The results show that the best Comparative Molecular Field Analysis 
(CoMFA) model has q2 = 0.742 and r2 = 0.973, and the best Comparative Molecular Similarity Indices Analysis (CoMSIA) model has q2 = 0.679 
and r2 = 0.918. For HQSAR the best model has q2 = 0.773 and r2 = 0.964. The r2 value for boostrap for CoMFA and CoMSIA are 0.98 and 0.97 
respectively. Pharmacophore mapping revealed varied bioactive regions of ligand. Thus, these compounds could be used as lead for designing 
the synthesis of potent alpha-glucosidase inhibitors. 
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INTRODUCTION 
Diabetes mellitus is a persistent metabolic disorder 
diagnosed by hyperglycemia, glycosuria, hyperlipidemia, 
negative nitrogen balance and sometimes ketonaemia. Over 
18 years of age the international occurrence of diabetes 
among adults has ascended from 4.7% in 1980 to 8.5% in 
2014 (Global report on diabetes. WHO, Geneva, 2016). In 
2030 diabetes would be the seventh leading cause of death 
as per the World Health Organization (WHO) (Mathers CD, 
Loncar D, 2006). The effects of diabetes mellitus include long 
term damage, dysfunction and of various organs. Adult-onset 
blindness, lower limb amputations and kidney failure are the 
major outcomes of diabetes (Alberti K, Zimmet Z.1999). 
A common and severe difficulty confronted by many people 
with type 2 diabetes is postprandial hyperglycemia, α-
glucosidase inhibitors (AGIs) are well suited for its treatment 
(Vats Rajesh.2005). Furthermore, α-glucosidase may also be 
used as therapeutic target for other carbohydrate mediated 
diseases including cancer, HIV and hepatitis. Alpha-
glucosidase is located in the brush border of the small 
intestine that acts upon 1, 4- alpha bonds. Most of the 
carbohydrates are present as oligo- or poly- saccharides, and 
have to be broken down to disaccharides, before sucrose, 
isomaltase, maltase, glycol-amylase, and lactase break them 
into digestible mono-saccharides (Kalra S., 2014). AGIs 
inhibits both alpha amylase and the other α-glucosidases, 
thus preventing absorption of starch and other 
carbohydrates from the brush border of the intestine. 
Benzo-hydrazides had been reported to possess various 
biological activities, which includes anti-leishmanial  (Taha 
et al., 2014b), anti-oxidant  (Aziz et al., 2014, Khan et al., 
2012), anti-glycation (Khan et al., 2013a, Khan et al., 
2013b, Khan et al., 2015, Jamil et al., 2015), anti-
bacterial  (Imran et al., 2014), and α-glucosidase inhibition 
(Taha et al., 2015f) activities. Benz-imidazole nucleus is an 
important pharmacophore with unique chemical and 
biological properties. Benzimidazoles have been found to 
possess anti-inflammatory (Kohno T, et. al. 1990), anti-
diabetic (Bhise UN, et. al. 2008), antispasmodic (Francisco 
AC, et. al. 2006), diuretics (Pashinski VG, et. al. 1978), 
analgesic (Kohno T, et. al. 1990), antimicrobial (Durmaz R, et. 
al. 2003), anti-helminthic (Solominova PS, et. al. 2004), anti-
HIV (Gardiner JM, et. al. 1995), antiulcer (Bariwal JB, 2008), 
anticancer (Gellis A, et. al. 2008), and anticonvulsant 
activities (Chimrri A, et al. 2001). 
Furthermore, recent studies have shown that some 
benzimidazole derivatives have been identified to exhibit α-
glucosidase inhibitory activity. In our work, we have 
combined benzohydrazide and benz-imidazole nucleus, and 
developed SAR based on 3D-QSAR, HQSAR studies and 
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Pharmacophore Mapping. Further from docking results, 11 
compounds were synthesized based on their dock scores. 
The synthesized compounds were tested for their in vitro α-
glucosidase inhibitory activity.  
MATERIALS AND METHOD 
Molecular modelling 
The molecular modeling studies (CoMFA, CoMSIA, HQSAR, 
and Pharmacophore mapping) were performed by means of 
the SYBYL-X 2.1.1 package (Tripos Inc., St. Louis, USA). 
Data set 
The biological data sets of 43 benzimidazole derivatives [(26 
compounds from the paper of Zawawi et al. (2016) and 19 
compounds from Taha et al. (2015) with α-glucosidase 
inhibitory activity were listed in Table 1. Structural 
variations of the parent structure, present in all molecules, 
were allowed at R position. Using the ligand preparation all 
the 2D structure of the compounds were standardized to 
generate a 3D conformation of compounds. They were 
minimized using Tripos force field (Matthew Clark, et al. 
2004) and Gasteiger-Huckel charge with termination 
gradient of 0.05 kcal/mol, maximum iteration of 1000, NB 
cutoff of 8.00 and distance-dependent dielectric constant of 
1.00. The IC50 values were converted to the corresponding 
pIC50 (-log IC50) and used as dependent variables in the QSAR 
analysis. 
Alignment 
One of the fundamental assumptions wherein 3D-QSAR 
studies are based is that a geometric similarity should exist 
between the structures to obtain valid and reliable models. A 
proper molecular alignment adjusts the geometry of the 
molecules such that its steric and electrostatic fields match 
the fields of the template molecule which is the most 
essential for the quality and the predictive ability of CoMFA 
and CoMSIA models. In the present study by using the align 
database function in Sybyl 2.1.1 the most active compound 
19 is used as a template (red color) for superimposition, 
which is assumed to represent the most bioactive 
conformation among the given set. All the molecules were 
aligned by the Align Database command available in Sybyl 
using maximum substructure.  Figure 1 shows the stereo 
view of all the aligned molecules (Agarwal A, et al. 1993, 
Baurin N, et al. 2000) 
Molecular Modelling 
The forty-three benzimidazole analogues exhibited 
significant α-glucosidase inhibitory activity (Table 1). In the 
series parent derivative 19 was chosen as template which 
have electron-donating groups at 3, 4, and 5 positions.  
RESULT AND DISCUSSION 
The structures of compounds used in training and test set 
shown in Table 1. Using the series of benzimidazole and 
benzimidazole benzhydrazide derivatives possessing α-
glucosidase inhibitory activity, 3D-QSAR models were 
derived. The CoMFA and CoMSIA models (Table 2 and 3) 
were developed using common substructure-based based 
alignment scheme.  
The grey color shows the carbon atom, cyan color shows the 
hydrogen atoms, blue color shows the nitrogen atoms and 
red color shows oxygen atom. 
During the molecular modeling process, 14 compounds out 
of the total 45 α-glucosidase inhibitors were selected as the 
testing set for model validation (1, 10, 14, 17, 20, 22, 24, 27, 
28, 33, 34, 35 and 38) and remaining in training set were 
selected by diversity method.  
Several statistical parameters including Rcv2, Rncv2, SEE and F 
values should be evaluated to judge whether a QSAR model is 
reliable for prediction of unknown molecules. The statistical 
results of the optimum models are summarized in Table 4. 
A high Rcv2 of 0.742 with five components was yielded by the 
statistical CoMFA model which provide an accurate internal 
predictive capacity of the model. Self-consistency was proven 
by a high Rncv2 of 0.973 with a low standard error estimate 
(SEE) of 0.08 for the final model. In case of the relative 
contributions, steric (S) and electrostatic (E) accounted for 
42.4% and 57.6% respectively, signified that the E field 
delivered more to the binding affinities. 
Actual pIC50 versus predicted pIC50 values for the training 
and test sets using CoMFA model is depicted in the scatter 
plot figure 2a. In CoMSIA, SEHD model displays good internal 
predictions relative to the CoMFA model, which ends in 
statistical results of Rcv2 0.70, Rncv2 0.938, F= 69.84 with four 
optimal components. Using CoMSIA model the actual pIC50 
versus predicted pIC50 values for the training and test sets 
the scatter plot is displayed in figure 2b. Clearly, all points 
are uniformly distributed around the regression line, 
suggesting the reliable predictive ability of the model. To 
validate the efficacy of the obtained models (CoMFA and 
CoMSIA) the test set molecules are further used.  
3-D QSAR Contour maps 
To view the field effects on the target features the 
stdev*coeff contour maps were constructed. The contour 
maps of CoMFA (steric and electrostatic), and CoMSIA (steric, 
electrostatic, and hydrophobic, donor) were shown in figure 
3 and figure 4, respectively. For visualization compound 19 
was labelled and displayed in the map. The area in the space 
where the aligned molecules would favorably or unfavorably 
interact with the enzyme is denoted by the CoMFA contour 
while those regions within the particular area where the 
presence of a group with a specific physicochemical property 
will be favored or disfavored for biological activity. 
Compound 19 was served as reference molecule. In the 
CoMFA steric field as shown in figure 4a, a large green 
contour polyhedron located around the R suggested that 
bulky groups had benefited well for the activity. This finding 
is clarified by the example that –OH substituent (4, 5, 6, 7, 9, 
10 and 12) in R region exhibited potent α-glucosidase 
inhibitory activity than molecules with and without –OH 
substituent at particular o-position, and p-position. Two 
yellow color contours indicated that bulky groups were 
steric unfavorable near benzimidazole nitrogen atom as 
steric clash might occur. Another small green contour on the 
4, 5-dimethylene group was consistent which would enhance 
the activity. 
The electrostatic field contour was demonstrated in figure. 
3b. A large blue polyhedral is observed outside the R 
substituent and around a small red isopleth at the R 
substituent which strongly restricts the sideward 
relocatability, also shows that electropositive substituents 
stretched to this contour would benefit for the inhibitory 
activity. Hydroxyl groups when present at o-position 
(compound 6) or one hydroxyl group and one methoxy 
group was present at o-position/p-position (compound 4, 10, 
12), bearing negative charge, increases the activity; while 
methyl at 2’, 3’ and 4’ position (compound 13, 14, 16) having 
positive charge decreases the activity. Electron donating 
substituents (compound 4, 5, 6, and 19) at R gives better 
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activity than electron withdrawing groups (compound 8, 22, 
25, and 26).  
In figure 4a the steric contour map of CoMSIA is displayed. 
Steric contour maps of CoMFA can be well compared with 
two green and two yellow contours of CoMSIA steric map. 
Likewise, the electrostatic contour map of CoMSIA is very 
similar to that of CoMFA map (Figure 4b). As the CoMSIA 
contour maps are very similar to those of CoMFA, merely 
hydrophobic contour map is discussed here. Yellow color at 
the R substituent and 4,5-dimethylene group shows bulky or 
hydrophobic substituents will favor the activity, while white 
contour near the hydrazide moiety and linker benzene ring 
shows disfavored areas for inhibitory activity (Figure 4c). A 
small white contour behind the yellow contour, indicates 
that size of the hydrophobic substituent may affect the 
inhibitory potency. It will show hydrophobic clashes with 
this region if any substituent extends to yellow polyhedral. 
The steric contour of CoMFA may perfectly coincide with 
results of hydrophobic contour. Purple color at the NH of 
imidazole and O of the linker, indicates that the bulky donor 
group is not desirable at these positions whereas the cyan 
color on the NH and benzene ring of the linker favors the 
substitution of a donor group. (Figure 4d) 
The best statistical parameter was obtained from the 
combination of atom, bond and donor atom (q2= 0.773, r2= 
0.964, Rse2= 0.103, qse2=0.255) based on the hologram length 
97 and 6 components. The HQSAR statistical model 
generated using default fragment size (4-7) with fragment 
distinct (A/B/DA) gave a cross-validated correlation 
coefficient (q2) of 0.773, non-cross-validated correlation 
coefficient (r2) of 0.964, low standard error estimate (SEE) of 
0.103 with an optimized component of 6, and Pred r2 of 
0.732 was obtained. Thus, the HQSAR model obtained here 
was reliable. The scatter plot for the actual pIC50 versus 
predicted pIC50 values for the training and test sets is 
displayed in figure 2 (c). On the basis of different colors 
HQSAR graphically delivers evidence on the atomic or 
fragment contributions to the activities. The colours at the 
green end (yellow, green-blue and green) reflect positive 
contribution, colours at the red end of the spectrum (red, 
red-orange and orange) reflect negative contribution and 
neutral contributions are coloured in white. The most active 
molecular fragments of compound 19, most potent α-
glucosidase compound of the data set are shown in figure 5. 
According to the contribution maps, the molecular fragments 
corresponding to the unsaturated ring are strongly related to 
biological affinity at C1, C2 and C6 (coloured in green and 
yellow). 
DISCO proposed Model 443 (Figure 6), a eleven point model 
(AL 02, DL 01, HY 03, AR 02, AS 02) with a tolerance of 1 Å. 
Hydrogen bond donor atoms (DL) and hydrogen bond 
acceptor atoms (AL) is the nitrogen of imidazole function, 
and (HY) is the center of the benzimidazole ring and linker 
benzene ring attached to hydrazide moiety. The nitrogen 
function of the inhibitor molecules is believed to mimic the 
ring oxygen group present in oligosaccharide and is 
confirmed as the primary site of binding. The enzymatic 
reaction would stop because the C-N linkage in the designed 
inhibitor molecule can’t be cleaved. As long as inhibitor 
bound to the alpha-glucosidase enzyme, ingested 
carbohydrates cannot be digested and glucose cannot be 
released for absorption. So, the benzimidazole moiety is 
important for the activity no changes should be made in that 
region. Results of pharmacophore hypothesis generated by 
DISCOtech are shown in Table 6.  Model 443 was considered 
as the best model as it had highest score of 4.4232 compared 
to remaining five hundred models. The pharmacophoric 
feature points and the interatomic distances between groups 
are presented in figure 6. 
After the DISCOtech, Genetic Algorithm with Linear 
Assignment of Hypermolecular Alignment of Database 
(GALAHAD) was runned, ten pharmacophore models were 
generated with population size set to 80-100 and other 
default parameters, for which statistical values are listed in 
Table 6. Therefore, Model_443 was considered to be the best 
model and its statistical values are listed in Table 9. As 
shown in Figure 7, this model contains three acceptor atoms, 
three donor atoms and three hydrophobes, and the nitrogen 
atoms of benzimidazole group acts both acceptor and donor 
atoms. 
The important key finding obtained from CoMFA, CoMSIA, 
HQSAR analysis and Pharmacophore mapping promotes us 
to suggest some novel α-glucosidase antagonist compounds. 
The molecular modelling analysis provided adequate 
information regarding the structural requirements for 
enhanced α-glucosidase inhibitory activity.  
The CoMFA, CoMSIA and HQSAR contours contribution maps 
guide us to optimize the accessible scaffold. Based on the 
molecular modelling recommendation without disturbing 
the pharmacophore bulky, electron donating, hydrophobic at 
the R position enhance activity; electron donating, electron-
withdrawing and hydrophobic substituent are favored at 
linker between the hydrazide and benzimidazole; and minor, 
fewer bulky substituents at benzimidazole assistance 
potency through CoMFA and CoMSIA. Moreover, HQSAR 
advice that saturated and linked aromatic side chain showed 
positive contribution. The group imidazole, hydrazide, -
NH[C=O] CH3, and -OH were essential for binding to the 
inhibitors site cavity (protomol). The structure activity 
relationship explored by this study is presented in figure 7.  
CONCLUSION  
In this study, 3D QSAR, HQSAR and Pharmacophore mapping 
analysis is described as a rational strategy for the design of 
novel alpha glucosidase inhibitors. All the models (CoMFA, 
CoMSIA and HQSAR) were found satisfactory according to 
the statistical parameters. CoMFA and CoMSIA models are 
found to be good according to the statistical results as well as 
the contour maps analysis. It can further be concluded from 
the results that the compounds may be due to bulky 
substitution of benzimidazole ring and existence of electron 
donating group on R. Based on the molecular modeling 
results the designed compounds can further be synthesized 
and biological evaluation can be done for alpha-glucosidase 
activity. 
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Table 1: Structures and inhibitory activity values of benzimidazoles derivatives 
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TEMPLATE ALIGNMENT 
Figure 1: a. Template molecule (19) used for the molecular alignment (core structure for alignment is shown in red) b. Three-
dimensional data set alignment. 
 
Table: 2 CoMFA model on different charges 
 
CHARGES q2 r2 SE 
NO. OF 
COMP. 
Gasteiger 0.706 0.913 0.150 4 
Gast Huckel 0.693 0.891 0.173 4 
Pullman 0.700 0.899 0.160 4 
Formal charges 0.592 0.791 0.234 3 
Delre 0.742 0.973 0.080 5 
MMFF94 0.701 0.889 0.174 4 
CoMFA on Delre charge 
clogP 0.443 0.948 0.12 5 
 
Table: 3 CoMSIA with different combinations on Delre charge 
 
COMBINATIONS q2 r2 SE NO. OF COMP. 
S 0.626 0.766 0.24 3 
E 0.634 0.883 0.175 3 
H 0.577 0.721 0.26 2 
D 0.624 0.878 0.18 4 
A 0.637 0.852 0.201 4 
S+ E 0.707 0.905 0.158 3 
S + E + H 0.7 0.915 0.153 4 
S + E + H + D 0.679 0.918 0.149 4 
S+ E+H+D+ A 0.667 0.875 0.1818 3 
 
Table: 4 The statistical results of the CoMFA and CoMSIA analyses for the training and test set compounds 
 
 CoMSIA CoMFA 
Rncv
2 0.938 0.973 
Rcv
2 0.70 0.742 
F (n1=5, n2=23) 69.84 164.78 
SEE 0.133 0.08 
R2pred. 0.729 0.732 
R2bootstrap 0.97 0.98 
SD 0.010 0.014 
Field contribution 
S 0.177 0.424 
E 0.634 0.576 
H 0.189 - 
D 0.009 - 
A - - 
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Figure 2a: Graph of actual versus predicted pIC50 values of the training set and the test set molecules of Model 2 (Delre) using the 
CoMFA model. 
 
Figure 2b: Graph of actual versus predicted pIC50 values of the training set and the test set molecules of Model 29 (MMFF94) using 
the CoMSIA model. 
 
 
(a) STERIC (b) ELECTROSTATIC 
Figure 3: Contour maps for CoMFA model. 
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(a) STERIC (b) ELECTROSTATIC 
 
 
(c) HYDROPHOBIC (d) DONOR 
Figure 4: Contour maps for CoMSIA model. 
 
Table 5: Summary of the statistical parameters of HQSAR studies: 
 
S.no. Statistical parameters model 
1. Fragment size 6-9 
2. Q2 0.731 
3. R2 0.974 
4. Ensemble 0.968 
5. SE 0.088 
6. NC 6 
7. Best length 257 
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Figure 2c: Graph of actual versus predicted pIC50 values of the training set and the test set molecules of Model A/B/DA at 6-9 
fragment size using the HQSAR 
 
 
Figure 5: HQSAR contour map for compound 19 (most active) 
 
 
Figure 6: Pharmacophoric feature points and the interatomic distances between groups 
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Table 6: Number of models obtained along with the pharmacophoric features and tolerance values of each of the DISCOTech 
pharmacophoric run 
 
Name Size Hits Score Tolerance DMEAN Activities 
MODEL_443 10 29 4.4232 0.25 3.6758 325.…00 
 
a. SIZE – number of features in the model, 
b. HITS – number of molecules that matched during the search, 
c. SCORE – an overall measure of fit and of overlap for the entire collection of structures, 
d. TOLERANCE – initial tolerance setting, 
e. DMEAN – average interpoint distance. 
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Figure 7: Structure activity relationship developed by the CoMFA, CoMSIA, HQSAR and Pharmacophore mapping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
